Kala was co-founded by Lux in 2009 alongside recognized experts in the field of nanomedicine, including professors Justin Hanes and Robert Langer, and pharmaceutical industry veteran Dr. Colin Gardner. The company is a clinical-stage pharmaceutical company focused on innovative, nanoparticle-based treatments for ocular diseases that affect the front and back of the eye. Kala leverages its proprietary mucus-penetrating, particle technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue. These treatments have the potential to provide greater efficacy over longer periods of time and replace injections with a simple eye drop.
Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.
Advancing Human Health
Lux founded: 2009
Initial Public Offering: 2017